TY - JOUR
T1 - CD8+CD11b+ peripheral blood T lymphocytes contain lymphokine‐activated killer cell precursors
AU - Dianzani, Umberto
AU - Zarcone, Daniela
AU - Pistoia, Vito
AU - Grossi, Carlo E.
AU - Pileri, Alessandro
AU - Massaia, Massimo
AU - Ferrarini, Manlio
PY - 1989/6
Y1 - 1989/6
N2 - CD3+CD8+ cells, purified from peripheral blood T cells by depletion of CD4+ lymphocytes, were tested for their cytotoxic activity against K‐562 or HL‐60 cells. Freshly prepared cells had no cytotoxic function, but upon exposure to recombinant interleukin 2 (rIL 2) in vitro they acquired a lymphokine‐activated killer (LAK) activity. Fractionation of CD3+CD8+ cells into CD11b+ and CD11b− cells demonstrated that all the cells with the potential of developing LAK cell functions were within the CD8+CD11b+ subset. These cells lacked natural killer cell markers such as CD16 or NKH1, but a proportion of them stained for Leu‐7. Furthermore, they expressed the α/β chains, but not the γ/δ chains, of the T cell receptor, as could be determined by staining with the appropriate monoclonal antibodies. CD8+CD11b+ cells had a large granular lymphocyte morphology, as shown by both cytochemical and electron microscopy analyses. They proliferated in response to IL 2 in vitro and developed cytotoxic functions against a number of natural killer resistant targets. Their response to phytohemagglutinin or pokeweed mitogen was very weak or absent. By contrast, CD8+CD11b− cells failed to generate LAK cells in response to rIL 2, did not show a large granular lymphocyte morphology, but responded vigorously to phytohemagglutinin or pokeweed mitogen. Purified CD8+CD11b+ cells were cloned by limiting dilution in the presence of rIL 2. The observed cloning efficiency of 19 ± 0.3% indicates that a fraction of the cells only could respond to IL 2. Furthermore, only 50% of the clones obtained had a LAK cell function. These data show that CD8+CD11b+ cells represent a heterogeneous cell population. Nevertheless this cell subset probably represents the major source of LAK cell progenitors within the circulating T cells.
AB - CD3+CD8+ cells, purified from peripheral blood T cells by depletion of CD4+ lymphocytes, were tested for their cytotoxic activity against K‐562 or HL‐60 cells. Freshly prepared cells had no cytotoxic function, but upon exposure to recombinant interleukin 2 (rIL 2) in vitro they acquired a lymphokine‐activated killer (LAK) activity. Fractionation of CD3+CD8+ cells into CD11b+ and CD11b− cells demonstrated that all the cells with the potential of developing LAK cell functions were within the CD8+CD11b+ subset. These cells lacked natural killer cell markers such as CD16 or NKH1, but a proportion of them stained for Leu‐7. Furthermore, they expressed the α/β chains, but not the γ/δ chains, of the T cell receptor, as could be determined by staining with the appropriate monoclonal antibodies. CD8+CD11b+ cells had a large granular lymphocyte morphology, as shown by both cytochemical and electron microscopy analyses. They proliferated in response to IL 2 in vitro and developed cytotoxic functions against a number of natural killer resistant targets. Their response to phytohemagglutinin or pokeweed mitogen was very weak or absent. By contrast, CD8+CD11b− cells failed to generate LAK cells in response to rIL 2, did not show a large granular lymphocyte morphology, but responded vigorously to phytohemagglutinin or pokeweed mitogen. Purified CD8+CD11b+ cells were cloned by limiting dilution in the presence of rIL 2. The observed cloning efficiency of 19 ± 0.3% indicates that a fraction of the cells only could respond to IL 2. Furthermore, only 50% of the clones obtained had a LAK cell function. These data show that CD8+CD11b+ cells represent a heterogeneous cell population. Nevertheless this cell subset probably represents the major source of LAK cell progenitors within the circulating T cells.
UR - http://www.scopus.com/inward/record.url?scp=0024334987&partnerID=8YFLogxK
U2 - 10.1002/eji.1830190613
DO - 10.1002/eji.1830190613
M3 - Article
SN - 0014-2980
VL - 19
SP - 1037
EP - 1044
JO - European Journal of Immunology
JF - European Journal of Immunology
IS - 6
ER -